Summary The incidence of a new primary non-germ cell malignancy was determined in 876 patients with testicular cancer treated at the Norwegian Radium Hospital from 1956 to 1977. Sixty-five patients developed a second cancer leading to a statistically significant increased relative risk (RR = 1.58), especially if extended radiotherapy had been given (RR = 4.13). The excess risks of developing lung cancer and malignant melanoma were 2.03 and 3.89, respectively. Increased RR for these two cancer types were seen both after extended radiotherapy and after radiotherapy combined with chemotherapy. Studies of the time between treatment and secondary lung cancer indicated that the development of the new lung cancer could be partly treatment related, whereas the raised incidence of malignant melanoma may be related to the frequent health checks performed in patients with testicular cancer. Patients who had received extended radiotherapy were also at an increased risk of developing cancer of the stomach and of the colon. Three cases of acute leukaemia were observed more than 5 years after treatment, all of them in patients who had received abdominal radiotherapy only. It is concluded that patients apparently cured of a testicular cancer have an increased risk of developing a new treatment related non-germ cell malignancy, in particular lung cancer. The application of the extended radiotherapy or the combination of radiotherapy and chemotherapy containing alkylating drugs should be avoided in order to reduce this excess risk.
Testicular cancer represents 1.25% of all male malignancies in Norway. Ninety per cent of the patients with testicular cancer are now cured (Peckham, 1988; Fossa et al., 1988) . As the mean age of patients with this malignancy is about 35 years, most of them will live for 30-40 years after treatment. The problem of treatment related long-term toxicity has therefore become important. Some authors have described organ-related side-effects occurring 5-10 years after radiotherapy and/or chemotherapy, such as nephrotoxicity, neurotoxicity, pulmonary, cardiovascular and gonadal toxicity (Roth et al., 1988; Fossa et al., 1988; Hansen et al., 1988; Aass et al., 1990) . Four larger series have dealt with the incidence of second non-germ cell tumours observed after treatment of testicular cancer (Cockburn et al., 1983; Hay et al., 1984; Kleinermann et al., 1985; Kaldor et al., 1987) . In these large studies the relation to treatment is, however, not always considered specifically. The objective of the present paper is to study the (Peckham et al., 1979) .
Treatment
Radiotherapy A detailed description of the treatment principles has been given elsewhere (Fossa et al., 1988) . High-voltage radiotherapy represented the main treatment modality. Radiotherapy was given by Betatrons 31 or 33 MV (1956) (1957) (1958) (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) or by linear accelerators (5-8 MV) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) . Patients with stage I disease received abdominal radiotherapy. The fields included the bilateral para-aortic lymph nodes and the ipsilateral iliac lymph nodes (Figure 1 ). The daily dose was 2 Gy. Five fractions were given weekly. If radiotherapy was delivered by Betatrons the iliac lymph nodes were irradiated by an anterior field only (field size approximately 12 x 15 cm), whereas the para-aortic lymph nodes were covered by a posterior field (field size approximately 12 x 15 cm). Both fields were treated daily. If linear accelerators were used, radiotherapy was given to an anterior and posterior abdominal field (L-field) and one field was treated daily. Seminoma patients were routinely treated with a total dose of 36-40 Gy; non-seminoma patients received 50 Gy to the abdominal fields. In patients with stage II and stage III tumours, additional radiotherapy (30-40 Gy) was given to mediastinal fields, including the left or both supraclavicular fossae (Figure 1 ).
For the purpose of this analysis the mid-plane dose to the mediastinum from scattered irradiation was estimated. In patients receiving 40 Gy from a Betatron to standard abdominal fields, the mediastinal dose was <20 cGy. The comparable dose in patients treated by a linear accelerator was 60-70 cGy. In the latter cases the superficial layers of the skin of the thorax were exposed to a dose of 100-120 cGy.
Chemotherapy Chemotherapy was given mainly to patients with stage IV disease or as secondary treatment in case of relapse.
The type of the cytostatic drugs and of the chemotherapy regimens has varied during the years. During the first 10 years cyclophosphamide was given as a single drug. During the years 1966-1975 the Li regimen (Li et al., 1960) and mithramycin (Klepp et al., 1975) were added to the therapeutic armamentarium. From 1975 From -1977 adriamycin based combination chemotherapy was the treatment of choice whenever systemic chemotherapy was considered (Klepp et al., 1977) .
Based on the given treatment, three subgroups of patients were identified (Table I) (1956) (1957) (1958) (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) ; b, linear accelerators (5-8 MV) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) .
Results
For the total series there was a significantly raised relative risk for the development of a new non-germ cell cancer (RR: (Smith & Doll, 1982; Kato & Schull, 1982) . As in these studies, the majority of the lung (Knudson, 1971) , initiated an intense search for tumour suppressor genes. Loss of specific DNA sequences in tumour cells have been shown for several familial and sporadic solid malignancies (Ponder, 1988) . Site-specific allele losses on chromosome 3p have been shown for renal cell carcinoma and for lung cancer (all types). Sequences on chromosome lip are lost in Wilms' tumour and bladder cancer as well as in certain types of lung cancer (Willey et al., 1988) . Recently we have shown that both these regions also are involved in testicular germ cell tumours (Lothe et al., 1989) .
The fact that both the 3p and lip chromosomal regions are shown to be involved in lung cancer strengthens the possibility of a genetic predisposition in a subset of testicular cancer patients who develop lung cancer after treatment. A genetic predisposition may be suggested by features like familiar occurrence of testicular neoplasms (Gedde-Dahl et al., 1985) , bilateral tumours and multiple primary malignancies. The excess risk of malignant melanoma is intriguing. Radiation exposure within the treatment fields or by scattered irradiation to the trunk elsewhere may represent one explanation. However, the highest incidence of malignant melanoma occurred as early as 1-4 years after the diagnosis of testicular cancer, making a relationship to treatment less probable. The increased incidence of malignant melanoma is partly due to the increased medical attention during the frequent follow-up examinations which testicular cancer patients undergo. As for lung cancer a common predisposing factor might be present. Hay et al. (1984) described an excess risk of skin cancer after the diagnosis of testicular cancer, not distinguishing between non-melanoma and melanoma. However, from these authors' discussion it becomes evident that most of the second skin cancers were non-melanoma registered in patients who (due to their primary testicular cancer) had more frequent and intensive health examinations than the general population.
An increased risk of transitional cell carcinoma in irradiated sites has been reported previously (Hay et al., 1984; Kleinermann et al., 1985) . This observation is partially confirmed in the present study by an increased RR of second bladder cancer, but again the hypothesis of the common predisposition cannot be rejected.
For the other solid tumour types the numbers are small and do not allow interpretation. However, in the future the incidence of a new cancer of the colon and stomach cancer should be evaluated in larger series. Kaldor et al. (1987) demonstrated an excess risk of rectal cancer after treatment for testicular cancer.
Only three cases of leukaemia were observed; all were acute leukaemia and all three patients had received abdominal radiotherapy as their only treatment. The RR was not significantly increased as compared to the overall incidence of leukaemia in the general population. However, for acute leukaemia there was a significantly increased RR among our patients. This is in line with observations of Kleinermann et al. (1985) and Redmann et al. (1984) , who found a statistically significant excess risk of acute leukaemia in patients treated for testicular cancer, after irradiation alone, after chemotherapy alone or after a combination of both treatment modalities. On the other hand, Hay et al. (1985) did not find an excess risk of acute leukaemia in irradiated testicular cancer patients. In the literature it is generally quoted that radiation or chemotherapy induced leukaemia usually occurs within 2-3 years after completion of treatment. However, in our three patients with acute leukaemia the malignancy was diagnosed 5 years or more after the treatment for testicular cancer (more than 15 years after in two patients). This observation makes any treatment relation less probable.
The introduction of cisplatin into the treatment of testicular cancer has dramatically changed the treatment policies in testicular cancer. Non-seminoma patients without metastases no longer receive adjuvant radiotherapy. In testicular cancer patients with metastases adriamycin or cyclophosphamide are used rarely. Cisplatin-based chemotherapy represents the principal therapy. Whether cisplatin-based chemotherapy increases the risk of secondary cancer is unknown. Alkylating agents, such as iphosphamide, are, however, still applied extensively in the modern therapy of both non-seminoma and seminoma, and abdominal radiotherapy is still the treatment of choice in low stage seminoma. The combination of chemotherapy with radiotherapy represents an actual therapeutic alternative in advanced seminoma. All these treatment modalities may increase the risk of a second non-germ cell malignancy in surviving patients.
We feel that the present series allows the following conclusions which are still relevant today. 1. The excess risk of a new non-germ cell cancer in the group of patients with extended radiotherapy or combined radiotherapy/chemotherapy should lead to reluctance to apply these treatment modalities routinely in testicular cancer patients, in particular if alkylating agents and/or adriamycin are applied. Such combination treatment should only be given if strongly indicated. 2. Due to a probable excess risk of lung cancer, the young testicular cancer patient should be warned against avoidable exposure to known carcinogens. In particular, he should be strongly advised not to smoke. 3. As our figures for an increased RR for some new cancers (bladder, stomach, colon) are only suggestive, and do not yield statistically significant differences, large co-operative studies are needed to confirm or disprove the observation. Such studies should take into account the different treatment modalities.
